NCT02786186Completed
A Registry of Patients With Moderate to Severe Plaque Psoriasis
A Registry of Patients With Moderate to Severe Chronic Plaque Psoriasis in Canada and Latin AmErica (LACan)
Source: ClinicalTrials.gov · Last updated 19 Feb 2026
Brief summary (registry, in English)
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2376 (actual)
- First submitted
- 6 May 2016
- Start date
- 23 Dec 2015
- Primary completion date
- 22 Jan 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Psoriasis
- NCT number
- NCT02786186
What you commit to
- Study type: Observational
- Participants enrolled: 2376
- From 23 Dec 2015 to the primary completion date, 22 Jan 2026
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days.
Other
- \- Unwillingness or inability to comply with the study requirements
Who the study is looking for
- \- Patients able to give written informed consent
- \- Patients at least 18 years of age at time of informed consent signature
- \- Confirmed diagnosis of chronic moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's clinical judgment at the time of recruitment.
- \- Patients initiating a treatment for psoriasis as per regional policy. This will include secukinumab, other biologics, systemic treatments, and phototherapy. Decision to treat with any of the above-mentioned treatments must have been reached prior to and independently of recruitment in the study.
- \- Treatments prescribed in accordance to the product monograph and regional regulatory and reimbursement policies
- \- Patients able to understand and communicate with the investigator and comply with the requirements of the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Investigative Site Coordinator of this site? Confirm its status | Brandon | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Fredericton | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Hamilton | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | London | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Nanaimo | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Nepean | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | St. John's | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Surrey | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Winnepeg | Canada | Unknown status |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Winnipeg | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.